Gilead ​Sciences said ‌on Thursday ​it ​will acquire ⁠PepStar ​Therapeutics' ​oral inflammation drug ​program, ​including an experimental ‌bowel ⁠disease treatment, ​for $1.275 ​billion ⁠in cash.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in